|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 320.00 CHF | -0.47% |
|
-0.59% | -2.50% |
| 05-13 | US FDA approves BeOne's drug for a type of blood cancer | RE |
| 05-13 | Roche Holding AG - Analyst/Investor Day |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | 1,210 | +19.12% | 29 | ||||||
| 252.96 | +9.78% | 24 | ||||||
| 252.93 | +21.31% | 29 | ||||||
| 221.99 | +19.29% | 21 | ||||||
| 155.38 | +4.09% | 21 | ||||||
| 129.74 | +14.36% | 27 | ||||||
| 307.99 | +2.94% | 23 | ||||||
| 352.23 | +4.69% | 30 | ||||||
| 157.96 | +18.73% | 28 | ||||||
| 29.15 | +12.29% | 27 | ||||||
| 62.96 | +11.65% | 25 | ||||||
| 549.5 | +21.29% | 28 | ||||||
| 97.1 | +33.52% | 23 | ||||||
| 20.3 | +7.64% | 20 | ||||||
| 10,096.67 | +29.36% | 15 | ||||||
| 80.78 | +44.61% | 17 | ||||||
| 6,043.53 | +16.4% | 15 | ||||||
| 48.58 | +27.94% | 19 | ||||||
| 40.27 | +11.1% | 11 | ||||||
| Average | 1,058.42 | +17.37% | 23 | ||||||
| Weighted average by Cap. | 698.46 | +15.41% | 25 |
- Stock Market
- Equities
- ROP Stock
- ROG Stock
- Sector Roche Holding AG
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition